• Clathrin-Mediated Entry of Grass Carp Reovirus: Mechanistic

  2026-05-27

  Wang et al. (2018) revealed that genotype III grass carp reovirus (GCRV104) enters host cells via clathrin-mediated, pH-dependent endocytosis, a pathway distinct from the caveolae-mediated routes targeted by polyene agents such as Nystatin. Their inhibitor profiling provides clarity on viral entry mechanisms and informs future antiviral strategies for aquatic pathogens.

• Super-Enhancer Hijacking of LINC01977 Drives Early LUAD Prog

  2026-05-27

  Zhang et al. uncover a novel mechanism in early-stage lung adenocarcinoma where super-enhancer activation hijacks the lncRNA LINC01977, promoting malignancy via the TGF-β/SMAD3 pathway. Their findings highlight new epigenetic targets for cancer biology research and point to key roles for transcriptional coactivator inhibition in disease progression.

• Baicalin Methyl Ester: Structural Insights and Translational

  2026-05-26

  Explore the structural biology and translational assay implications of Baicalin methyl ester, an esterified derivative of baicalin, with deep analysis of molecular action and practical workflow design. Discover how this compound uniquely advances LPS-induced intestinal barrier research.

• Bufalin–CRISPR Nanomedicine Induces Pyroptosis for CRC Immun

  2026-05-26

  Liu et al. developed a calcium lactate nanoparticle system co-delivering bufalin and CRISPR/Cas9 RNPs targeting CD47 to trigger both pyroptosis and apoptosis in colorectal cancer, while reprogramming tumor-associated macrophages to enhance antitumor immunity. This dual-action approach represents a significant advance in synergistic cancer immunotherapy and provides a new strategy for overcoming immune resistance.

• Nystatin (Fungicidin): Applied Antifungal Workflows & Assay

  2026-05-25

  Nystatin (Fungicidin) stands out as a polyene antifungal for robust inhibition of Candida and mycoplasma in both classical and advanced research models. This guide walks you through experimental workflows, protocol parameters, and troubleshooting strategies to maximize reliability and translational impact—anchored by recent findings on drug action and endocytic pathway specificity.

• Homoharringtonine: Precision Targeting in Leukemia and Antiv

  2026-05-25

  Discover the molecular precision of Homoharringtonine, a cytotoxic alkaloid redefining leukemia and SARS-CoV-2 research. This article uniquely analyzes its mechanism, translational bridges, and protocol optimization for advanced scientific applications.

• Clathrin-Mediated Endocytosis in Grass Carp Reovirus Entry

  2026-05-24

  Wang et al. (2018) investigated the mechanisms of cell entry for type III grass carp reovirus (GCRV104) and demonstrated that clathrin-mediated, dynamin-dependent endocytosis is essential for infection. Their inhibitor analysis clarifies viral entry pathways, guiding future antiviral strategies and comparative virology research.

• Moxidectin Potentiates Nystatin via Ergosterol Elevation in

  2026-05-23

  A 2024 study reveals that moxidectin activates ergosterol biosynthesis in Candida albicans, increasing the efficacy of polyene antifungals like Nystatin against oral candidiasis. This mechanistic insight suggests new strategies to overcome resistance and optimize treatment of fungal infections.

• Propranolol: Bridging Mechanism and Strategy in Translationa

  2026-05-22

  This article delivers a thought-leadership perspective on propranolol, a non-selective β-adrenergic receptor blocker, uniting mechanistic insights with actionable guidance for translational researchers. Integrating critical findings on cardiovascular, neurological, and metabolic domains, it highlights protocol design, strategic positioning, and future outlook—demonstrating how APExBIO’s propranolol enables next-generation translational workflows.

• Dual Inhibition of Mycobacterial Terminal Oxidases by Pretom

  2026-05-22

  This study elucidates how pretomanid, a bicyclic nitroimidazole derivative, exerts bactericidal effects against Mycobacterium tuberculosis by simultaneously inhibiting both respiratory terminal oxidases. The findings highlight the potential for rational drug combinations targeting oxidative phosphorylation to enhance tuberculosis therapy and limit resistance.

• CFDA SE Cell Tracer Kit: Technical Guidance for Stable Cell

  2026-05-21

  The CFDA SE (carboxyfluorescein diacetate succinimidyl ester) Cell Tracer Kit enables robust, long-term fluorescent labeling for tracking cell proliferation and lineage in both in vitro and in vivo assays. This kit is most appropriate for applications that require stable, covalent cell tagging, and is unsuitable for workflows needing reversible or fleeting cell labeling.

• Comparative In Vitro Efficacy of Sisomicin and Tobramycin Ag

  2026-05-21

  This article reviews a landmark study investigating the in vitro activity of sisomicin, a novel aminoglycoside antibiotic, compared to established agents such as gentamicin and tobramycin. The paper's findings clarify the nuanced activity profiles of these antibiotics against a range of Gram-negative and Gram-positive clinical isolates, informing both resistance surveillance and experimental design in microbiology research.

• Nystatin (Fungicidin): Protocols, Applications, and Optimiza

  2026-05-20

  Nystatin (Fungicidin) stands out as a precision antifungal tool for targeted research on Candida and Aspergillus, with clear advantages in membrane disruption and resistance profiling. This article delivers actionable guidance on experimental workflows, troubleshooting, and protocol optimization, grounded in the latest research and product intelligence.

• SN-38 and Camptothecin Disrupt FUBP1–FUSE Binding in Cancer

  2026-05-20

  The referenced study identifies a novel mechanism by which camptothecin and its active analog SN-38 inhibit the DNA-binding activity of the oncogenic regulator FUBP1, in addition to their established topoisomerase I inhibition. These findings suggest dual-pathway interference that may enhance the therapeutic potential of SN-38 in advanced cancer research.

• Syringin Targets EGFR/PI3K/Akt to Enhance Sunitinib in RCC M

  2026-05-19

  The reference study demonstrates that Syringin, a natural product, inhibits renal cell carcinoma (RCC) progression by modulating the EGFR/PI3K/Akt pathway and enhances the efficacy of sunitinib. These findings support Syringin's potential role in overcoming drug resistance in RCC and inform future research on bioactive compounds in targeted cancer therapy.

15232 records 1/1016 page Next 12345 下5页 Last page